A director at Paycom Software Inc sold 1,500 shares at 249.959USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company’s Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan CELEBRATION, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra,” or the “Company”), a commercial-stage company focused on providing therapies to people living with rare disease, announced that based on the final vote count certified by the independent Inspector of Electi...
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors’ Recommendation and Vote “FOR” Wendy L. Dixon, Ph.D. and Tamara A. Favorito on the WHITE Proxy Card and “WITHHOLD” for Mangless Nominees CELEBRATION, Fla., May 21, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra,” or the “Company”), a commercial-stage...
Zevra Reports First Quarter 2025 Financial Results and Corporate Update Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive the Company’s commercial launches and development programs Company to host conference call and webcast today, May 13, 2025, at 4:30 p.m. ET CELEBRATION, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living w...
Barnes & Noble Education Announces Surge in New Campus Store Partnerships Over 20 new institutions across a mix of two- and four-year public and private colleges and universities turn to Barnes & Noble College for innovative, customer-focused solutions BASKING RIDGE, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- (NYSE: BNED), a leading solutions provider for the education industry, today announced a wave of new campus store partnerships with colleges and universities across the country. These institutions, representing a diverse mix of two- and four-year public and private schools, have selec...
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025 CELEBRATION, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the first quarter 2025 on Tuesday, May 13, 2025. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ...
Zevra Therapeutics to Participate in the Citizens Life Science Conference CELEBRATION, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that members of Zevra’s executive leadership team will participate in a fireside chat at the Citizens Life Science Conference in New York, NY, on Wednesday, May 7, 2025, at 11:30 a.m. ET. Additionally, management will be available for one-on-one meetings with registered attendees at each conference. The live webcasts will be acce...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.